According to Dr Livingston's editorial in the October 2007 issue of the Archives,1 the bariatric surgery community should “generate studies that provide compelling evidence that these operations are safe and cost-effective and cause long-lasting comorbidity control . . . by perform[ing] carefully designed, prospective, multicenter randomized controlled trials free from surgeon or industry bias.” Livingston goes on to suggest that a study by Wagner and colleagues2 in the same issue provides a convincing argument that society should pay for Roux-en-Y gastric bypass (RYGB) for patients with Medicaid because it would allow them to return to work and to be taken off public assistance.
Tishler CL, Reiss NS. Roux-en-Y Gastric Bypass May Not Increase Patients’ Return to Work. Arch Surg. 2008;143(10):1024-1025. doi:10.1001/archsurg.143.10.1024-b